clinical trial · NCT04838639
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects
Otsuka Pharmaceutical Factory, Inc.·phase1·completed·n = 84
ObesityNO-13065Placebo
brief summary
This clinical trial is the first-in-human study of NO-13065. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses and food effect of NO-13065 in healthy and obese adult subjects.
started
Jun 14, 2021
primary completion
Mar 31, 2022
completion
Mar 31, 2022
last updated
Nov 2, 2023
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 When Administered Orally to Healthy and Obese Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol